AN RINVR SCORING EVALUATION OF ONDANSETRON, DEXAMETHASONE, AND RANITIDINE AS ANTIEMETICS IN BREAST CANCER CHEMOTHERAPY

NAJMIATUL FITRIA; RONA SALSABILA RIVALDI; DITA PERMATASARI

doi:10.22159/ijap.2025.v17s1.15

Authors

NAJMIATUL FITRIA Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Andalas, Padang, Indonesia https://orcid.org/0000-0002-3255-1961
RONA SALSABILA RIVALDI Faculty of Pharmacy, Universitas Andalas, Padang, Indonesia
DITA PERMATASARI Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Andalas, Padang, Indonesia

DOI:

https://doi.org/10.22159/ijap.2025.v17s1.15

Keywords:

Breast cancer, ACTH chemotherapy, Antiemetic, Nausea and vomiting

Abstract

Objective: Antiemetics is used to control Chemotherapy-Induced Nausea and Vomiting (CINV) in breast cancer patients undergoing ACTH (Adriamycin, Cyclophosphamide, Docetaxel, Herceptin) chemotherapy. This study aimed to assess the effectiveness of an antiemetic regimen consisting of Ondansetron, Dexamethasone, and Ranitidine combination using (Rhodes Index Nausea Vomiting and Retching) RINVR scoring. Additionally, to evaluate the difference in CINV incidence in ACTH cycles.

Methods: A prospective cross-sectional study was conducted from March to June 2024 at Dr. M. Djamil. General Hospital Padang. The study determined the effect of antiemetic administration at the measurement time of 12 h, 24 h, 48 h, 72 h, and 96 h after chemotherapy. There were 30 respondents who met the inclusion criteria in this study. The instrument RINVR (Rhodes Index Nausea Vomiting and Retching) measured the vomit and nausea incidence.

Results: There were differences in the incidence of emesis between ACH dan TH cycles at measurement times of 12 h, 48 h, and 72 h (p-value<0.05). The effect of antiemetic administration showed significant results in the 48 h ACH cycle, which indicates that the higher the cycle, the lower the RINVR score.

Conclusion: The administration of antiemetics was notably effective at the 48 h mark in the ACH cycle, demonstrating a correlation between higher chemotherapy cycles and lower RINVR scores. These findings highlight the importance of tailored antiemetic strategies to improve patients' comfort and treatment outcomes.

References

Organization WH, WHO. Breast Cancer; 2023.

Sung HH, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A. Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-49. doi: 10.3322/caac.21660, PMID 33538338.

Nindrea RD, Aryandono T, Lazuardi L, Dwiprahasto I. Family history of breast cancer and breast cancer risk between Malays ethnicity in Malaysia and Indonesia: a meta-analysis. Iran J Public Health. 2019;48(2):198-205. doi: 10.18502/ijph.v48i2.814, PMID 31205873.

Trayes KP, Cokenakes SE. Breast cancer treatment. Am Fam Physician. 2021;104(2):171-8. PMID 34383430.

Smolarz B, Nowak AZ, Romanowicz H. Breast cancer-epidemiology, classification, pathogenesis and treatment (review of literature). Cancers (Basel). 2022;14(10):2569. doi: 10.3390/cancers14102569, PMID 35626173.

Divya G, Kumar JK, Praven A, Smitha P. Lakhs mi R. A study to assess knowledge, attitude and practice on breast cancer among women in Government General Hospital. Asian J Pharm Clin Res. 2021;14(2):60-5.

Bhosale RR, Janugade BU, Chavan DD, Thorat VM. Current perspectives on applications of nanoparticles for cancer management. Int J Pharm Pharm Sci. 2023;15(11):1-10. doi: 10.22159/ijpps.2023v15i11.49319.

Desriani A, Azamris SS, Ghaissani SS, Kinanti SR, Warisman MA, Fitria N. Design and characterization of a SYBR Green I-based melting curve method for investigation of HER2I655V polymorphism in breast cancer. J Genet Eng Biotechnol. 2021;19(1):6. doi: 10.1186/s43141-020-00108-9, PMID 33428029.

Jang BS, Han W, Kim IA. Tumor mutation burden, immune checkpoint crosstalk and radiosensitivity in single-cell RNA sequencing data of breast cancer. Radiother Oncol. 2020;142:202-9. doi: 10.1016/j.radonc.2019.11.003, PMID 31767471.

Desriani D, Azamris A, Rustamadji P, Abna IM, Ibadurrahman I, Fuad AM. Sensitive detection of PIK3CA exon 20 H1047R breast cancer based on low-cost intercalary dye SYBR green i real-time qPCR assay. Sains Malays. 2024;53(11):3683-93. doi: 10.17576/jsm-2024-5311-12.

Pusztai L, Yau C, Wolf DM, Han HS, Du L, Wallace AM. Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials. Ann Oncol of F J Eur Soc Med Oncol. 2022;32(5):1277-92.

Xu B, Li W, Zhang Q, Shao Z, Li Q, Wang X. Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (puffin): a phase III, randomized, double-blind, placebo-controlled study. Breast Cancer Res Treat. 2020;182(3):689-97. doi: 10.1007/s10549-020-05728-w, PMID 32564260.

Lin YY, Gao HF, Yang X, Zhu T, Zheng XX, Ji F. Neoadjuvant therapy in triple-negative breast cancer: a systematic review and network meta-analysis. Breast. 2022;66:126-35. doi: 10.1016/j.breast.2022.08.006, PMID 36265208.

Dipiro J, Yee G, Posey M, Haines S, Nolin T, Ellingrod V Annals of Pharmacotherapy. Pharmacotherapy: a pathophysiologic approach. 11th ed. 11th ed. McGraw-Hill Companies Incorporated; 2020.

Yeo W, Lau TK, Li L, Lai KT, Pang E, Cheung M. A randomized study of olanzapine-containing versus standard antiemetic regimens for the prevention of chemotherapy-induced nausea and vomiting in Chinese breast cancer patients. Breast. 2020;50:30-8. doi: 10.1016/j.breast.2020.01.005, PMID 31978815.

Uchida E, Lei MM, Roeland E, Lou U. Evaluating the incidence of chemotherapy-induced nausea and vomiting in patients with B-cell lymphoma receiving dose-adjusted EPOCH and rituximab. J Oncol Pharm Pract. 2022;28(1):119-26. doi: 10.1177/1078155220985919, PMID 33435826.

Fitria N, Wulansari S, Sari YO. Potential interactions analysis of antihypertensive drugs used in geriatric. Int J App Pharm. 2023;15 Special Issue 1:29-33. doi: 10.22159/ijap.2023.v15s1.47503.

Nawa Nishigaki M, Kobayashi R, Suzuki A, Hirose C, Matsuoka R, Mori R. Control of nausea and vomiting in patients receiving anthracycline/cyclophosphamide chemotherapy for breast cancer. Anticancer Res. 2018;38(2):877-84. doi: 10.21873/anticanres.12297, PMID 29374715.

Al-Salloum HF, Al-Harbi HE, Abdelazeem A. Effectiveness of antiemetic in reducing chemotherapy-induced nausea and vomiting in adult patients; An oncology center experience. J Oncol Pharm Pract. 2023;29(6):1317-25. doi: 10.1177/10781552221118634, PMID 36518002.

Fitria N, Lailaturrahmi L, Sukma A. The effect of consuming fermented milk containing probiotics during pregnancy the effect of consuming fermented milk containing probiotics during pregnancy. IOP Conf Ser Earth Environ Sci. 2024;1341(1):1-7.

Fleming MK, Carr A, Li J, Lundberg JD, Rogers KA. Antiemetic medication efficacy during EPOCH and R-EPOCH treatment. J Oncol Pharm Pract. 2021;27(7):1691-8. doi: 10.1177/1078155220967722, PMID 33092500.

Yeo W, Chan VT, Li L, Lau TK, Lai KT, Pang E. Dataset on chemotherapy-induced nausea and vomiting (CINV) and quality of life (QOL) during multiple chemotherapy cycles among a Chinese breast cancer patient population who were randomized to antiemetic regimens with or without olanzapine. Data Brief. 2020;30:105421. doi: 10.1016/j.dib.2020.105421, PMID 32215313.

Shinn HK, Lee MH, Moon SY, Hwang SI, Lee CS, Lim HK. Post-operative nausea and vomiting after gynecologic laparoscopic surgery: comparison between propofol and sevoflurane. Korean J Anesthesiol. 2011;60(1):36-40. doi: 10.4097/kjae.2011.60.1.36, PMID 21359079.

Nelwati N, Noviyani D. The effect of diaphragmatic breathing on nausea, vomiting and functional status among breast cancer patients undergoing chemotherapy. Eur J Oncol Nurs. 2024;70:102548. doi: 10.1016/j.ejon.2024.102548, PMID 38513453.

Rhodes VA, McDaniel RW. The index of nausea, vomiting, and retching: a new format of the lndex of nausea and vomiting. Oncol Nurs Forum. 1999;26(5):889-94. PMID 10382187.

Gupta K, Walton R, Kataria SP. Chemotherapy-induced nausea and vomiting: pathogenesis, recommendations, and new trends. Cancer Treat Res Commun. 2021;26:100278. doi: 10.1016/j.ctarc.2020.100278, PMID 33360668.

Song Z, Wang H, Zhang H, Zhao K, Zhang M, Yang F. Efficacy and safety of triple therapy with aprepitant, ondansetron, and prednisone for preventing nausea and vomiting induced by R-CEOP or CEOP chemotherapy regimen for non-Hodgkin lymphoma: a phase 2 open-label, randomized comparative trial. Leuk Lymphoma. 2017;58(4):816-21. doi: 10.1080/10428194.2016.1213838, PMID 27545191.

Majem M, de las Penas R, Virizuela JA, Cabezon Gutierrez L, Cruz P, Lopez Castro R. SEOM clinical guideline update for the prevention of chemotherapy-induced nausea and vomiting (2021). Clin Transl Oncol. 2022;24(4):712-23. doi: 10.1007/s12094-022-02802-1.

Kementerian Kesehatan RI. Pedoman nasional pelayanan Kedokteran tata Laksana kanker payudara. Jakarta. Kementerian Kesehatan Republik Indonesia; 2019.

Roila F, Molassiotis A, Herrstedt J, Aapro M, Gralla RJ, Bruera E. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol. 2016;27 Suppl 5:v119-33. doi: 10.1093/annonc/mdw270, PMID 27664248.

Jamali J, Dayo A, Adeel A, Qureshi Y, Khan T, Begum S. A survey on gastrointestinal adverse drug reactions of doxorubicin and cyclophosphamide combination therapy. J Pak Med Assoc. 2018;68(6):926-8. PMID 30325912.

Uchida M, Nakamura T, Makihara Y, Suetsugu K, Ikesue H, Mori Y. Comparison of antiemetic effects of granisetron and palonosetron in patients receiving Bendamustine-based chemotherapy. Pharmazie. 2018;73(5):304-8. doi: 10.1691/ph.2018.7948, PMID 29724299.

Naito Y, Kai Y, Ishikawa T, Fujita T, Uehara K, Doihara H. Chemotherapy-induced nausea and vomiting in patients with breast cancer: a prospective cohort study. Breast Cancer. 2020;27(1):122-8. doi: 10.1007/s12282-019-01001-1, PMID 31407150.

Thibeault C, Bardtke L, Vanshylla K, di Cristanziano V, Eberhardt KA, Stubbemann P. Short- and long-term T cell and antibody responses following dexamethasone treatment in COVID-19. JCI Insight. 2023;8(8):e166711. doi: 10.1172/jci.insight.166711, PMID 36881474.

Watanabe D, Iihara H, Fujii H, Makiyama A, Nishida S, Suzuki A. One-day versus three-day dexamethasone with NK1RA for patients receiving carboplatin and moderate emetogenic chemotherapy: a network meta-analysis. Oncologist. 2022;27(6):e524-32. doi: 10.1093/oncolo/oyac060, PMID 35427418.

Celio L, Bonizzoni E, Montani E, Aapro M. Efficacy of the dexamethasone-sparing triplet regimen for preventing cisplatin-induced emesis: a combined analysis. Future Oncol. 2022;18(30):3389-97. doi: 10.2217/fon-2022-0330, PMID 36017782.

Tashiro T, Takeuchi Y, Sakurai Y, Arai M, Shibata M, Tazaki S. Comparative study of a proton pump inhibitor with a histamine H2 receptor antagonist in Japanese patients with functional dyspepsia. Showa Univ J Med Sci. 2018;30(1):43-52. doi: 10.15369/sujms.30.43.

Cox JM, van Doorn L, Malmberg R, Oomen-de Hoop E, Bosch TM, van den Bemt PM. The added value of H2 antagonists in premedication regimens during paclitaxel treatment. Br J Cancer. 2021;124(10):1647-52. doi: 10.1038/s41416-021-01313-0, PMID 33762718.

Smit T, Van Eeden RI, Rapoport BL. High incidence of nausea during initial and repeated courses if intravenous chemotherapy in patients receiving guideline consistent antiemetic prophylaxis: a prospective, observational, real-world study. Ann Oncol. 2019;30. doi: 10.1093/annonc/mdz265.015.

Smit T, Kotze I, du Plessis J. The incidence of nausea in the absence of vomiting in patients receiving intravenous chemotherapy. Ann Palliat Med. 2021;10(3):2679-86. doi: 10.21037/apm-19-453, PMID 33549001.